Panax ginseng and its active ginsenosides (e.g., Rg1) have been shown to alleviate intestinal barrier disruption and suppress pro-inflammatory cytokines in CLP-induced sepsis, potentially through inhibition of the TLR4/NF-κB pathway, leading to reduced IL-6 and TNF-α levels (37). The gene discussed is NFKB1; the disease is Sepsis.